On March 1, 2018, iVF Riga Clinic and iVF Riga Stem Cell Centre will organize and hold free scientific and practical medical conference "Opportunities for using postnatal stem cells in oncology and oncohematology". Venue: Radisson Blu Latvija Conference & Spa Hotel (Elizabetes 55, Riga).
Conference’s audience is doctors of various specializations, as well as biotechnologists, laboratory specialists interested in cell technologies issues. However, the conference is of special interest for oncologists, oncohematologists, who wish to receive the latest knowledge about the possibilities of cellular therapy in oncology.
And it was the main aim why iVF Riga clinic invited a world-famous and experienced scientist who has worked for the last 25 years in the field of hematology, bone marrow transplantation for haematological malignancies. Professor Arnon Nagler, MD, Director of the Division of Hematology; Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center (Israel). Professor of Medicine at the Tel Aviv University (Israel). Professor Nagler’s main contributions and scientific interests include hematpoietic stem cell transplantation, haematological malignancies, cord blood biology and transplantation and adoptive cell-mediated immunotherapy including NK cell biology. Prof. Nagler will share his experience in the lecture “Cord Blood Transplantation for Hematological Malignancies focusing on acute Leukemia”.
Very important expertise in the field of transplantation of mesenchymal stromal stem cells and hematopoietic stem cells will share Alexandra A. Aizenshtadt, PhD (Research Laboratory of cell technologies of North-Western State Medical University n. a. I. I. Mechnikov).
Dr. Violeta Fodina, head of iVF Riga clinic, will present our Stem Cell Centre, tells about its importance for Latvia, possibilities and prospects of development.
The aim of the conference is to focus medical specialists on the possibilities of stem cell application in hematology, in the treatment of various severe and even considered incurable oncological diseases.
More information about the conference